Asparkam-Pharmlend

General characteristics. Structure:

Active ingredients: 7,9 g of magnesium of asparaginate, 11,6 g of potassium of asparaginate, 20 g of sorbitol in 1 l of solution.

Excipient: waters for injections.

Drug promotes elimination of deficit of potassium and magnesium, has antiarrhytmic effect, improves a metabolism in a myocardium, normalizes electrolytic balance.

Pharmacological properties:

Pharmacodynamics. Drug promotes elimination of deficit of potassium and magnesium, has antiarrhytmic effect, improves a metabolism in a myocardium, normalizes electrolytic balance. Is a donor of potassium ions and magnesium, promotes their penetration into intracellular space. Coming to cells, asparaginate joins in metabolism processes. Mg ions ++ reduce excitability of neurons, slow down neuromuscular transmission, participate in many enzymatic reactions, activate Na+-K+-ATF-azu, deleting from Na cell + and returning K+, reduce concentration of Na+, interfere with exchange of Na + on Ca ++ in unstriated muscles of vessels, lowering their resistance.

Ions stimulate with K+ ATP synthesis, is glucogenic, proteins, acetylcholine, etc., reduce excitability and conductivity of a myocardium, in big concentration oppress automatism. Both ions participate in maintenance of intracellular osmotic pressure, processes of carrying out and transfer of nervous impulses, reduction of skeletal muscles.

Pharmacokinetics. Ions by K+ and Mg ++ are quickly and fully soaked up and distributed on all body tissues. Potassium concentration in a blood plasma remains raised rather not for long because of bystry receipt it in cells and removal from an organism.

The considerable share of ions of Mg ++ in plasma (25-30%) forms complex connections with proteins. Ions by K+ and Mg ++ are excreted preferential with urine, in small amounts - with excrements, then, tears, etc. At a renal failure removal of ions of K+ and Mg ++ can be slowed down.

Indications to use:

The arrhythmias caused by a hypopotassemia, arrhythmias at intoxication cardiac glycosides, ventricular premature ventricular contraction; stenocardia, a myocardial infarction, heart failure (as supportive application); correction of the hypopotassemia (caused by saluretics, purgatives, steroid hormones, chronic vomiting, etc.). Drug is used also for preliminary and subsequent therapy of cardiac patients.

Route of administration and doses:

The drug is administered intravenously kapelno on 300-500 ml of solution by 1-2 times a day with a speed of 20-25 thaws a minute. The dose and duration of administration of drug is defined individually depending on indications to use and degree of a hypopotassemia.

In a week to and in a week after cardiac intervention enter 300-500 ml a day daily.

Features of use:

Use of drug is not recommended in the presence of AV of blockade.

Side effects:

At administration of drug nausea, dizziness, disturbance of intra ventricular conductivity, face reddening, phlebitis, lowering of arterial pressure, a hyporeflexia, respiratory depression, spasms are possible.

Interaction with other medicines:

Reduces effect of cardiac glycosides. Simultaneous use of kaliysberegayushchy diuretics can lead to a hyperpotassemia and a gipermagniyemiya. When mixing with other injection solutions there can be opacification or opalescence, such mixes should not be entered.

Contraindications:

Drug is contraindicated at an acute and chronic renal failure, a hyperpotassemia, a gipermagniyemiya, an atrioventricular block, a heavy myasthenia.

Overdose:

Symptoms: the overdose is followed by symptoms of a hyperpotassemia and a gipermagniyemiya.

Therapy provides intravenous administration of solutions of salts of calcium and sodium, intravenous drop administration of glucose with insulin (1 PIECE of insulin on each 3-5 g of glucose). At the peripheral paresis caused by toxic action of ions of Mg ++, especially at paralysis of respiratory muscles administration of physostigmine is possible.

In the presence of a renal failure extrarenal removal can be carried out by a hemodialysis or peritoneal dialysis.

Storage conditions:

In the place protected from light at a temperature from +5 to +25 °C. Period of validity 2 years.

Issue conditions:

According to the recipe

Packaging:

On 250 or 500 ml in polymeric containers.